What changed in Teva Pharmaceutical Industries Limited's latest annual report
In the year ended 31 Dec 2025, Teva Pharmaceutical Industries Limited's revenue rose 4.3% to USD 17.26bn, from USD 16.54bn; shareholders' equity rose 47.2% to USD 7.91bn, from USD 5.37bn; cash and cash equivalents rose 7.8% to USD 3.56bn, from USD 3.30bn.
Year ended 31 Dec 2025. Source: 10-K filed 3 Feb 2026, read it on SEC EDGAR.
USD 16.54bn to USD 17.26bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 16.54bn | 17.26bn | Up 4.3% |
| Net income | -1.64bn | 1.41bn | Not comparable |
| Total assets | 39.33bn | 40.75bn | Up 3.6% |
| Total liabilities | 33.61bn | 32.83bn | Down 2.3% |
| Cash and cash equivalents | 3.30bn | 3.56bn | Up 7.8% |
| Shareholders' equity | 5.37bn | 7.91bn | Up 47.2% |
Questions people ask
Did Teva Pharmaceutical Industries Limited's revenue grow last year?
Revenue grew 4.3%, from USD 16.54bn to USD 17.26bn in the year ended 31 Dec 2025.
Is Teva Pharmaceutical Industries Limited profitable?
Yes. Net income was USD 1.41bn in the year ended 31 Dec 2025. The year before: a net loss of USD 1.64bn.
How much cash and debt does Teva Pharmaceutical Industries Limited have?
At its latest year end (31 Dec 2025), Teva Pharmaceutical Industries Limited reported cash and cash equivalents of USD 3.56bn.
Where do these numbers come from?
From Teva Pharmaceutical Industries Limited's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Teva Pharmaceutical Industries Limited?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%